Finland

Blossom currently tracks 10 psychedelic clinical trials connected to Finland. The country page also links to 2 stakeholders and 2 events, giving the page ecosystem context beyond registered studies.

Ask Blossom about this country

Data updated May 4, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inFinland.

1
Blossom tracks 10 psychedelic clinical trials connected to Finland, with none currently marked active.
2
Visible trial compounds include Esketamine, Ketamine and Psilocybin.
3
Visible trial topics include Treatment-Resistant Depression (TRD), Major Depressive Disorder (MDD) and Alcohol Use Disorder (AUD).
4
The country page links to 2 stakeholders and 2 events in Blossom's ecosystem data.
5
The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.

Research and Access Snapshot

Blossom currently tracks 10 psychedelic clinical trials connected to Finland.

Active trials: 0
Total trials: 10
Stakeholders: 4
Events: 3

Top Compounds

Esketamine(6)
Ketamine(3)
Psilocybin(2)

Medical Access

Finland maintains a restrictive controlled-substance regime: pharmaceutical esketamine (Spravato) is an authorised medicine in the EU and available in Finland under prescription and supervised administration, while generic ketamine is an established medical anaesthetic (and occasionally used off-label in psychiatric emergency settings) but psychedelic classical compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT plant preparations, mescaline, and 2C-X) are scheduled as narcotics with no routine medical reimbursement except in authorised...

View trials→View stakeholders→View events→Open access guide→

Regulatory Status

The linked medical access and reimbursement guide summarises Finland as "Medical Only (Private)". Finland maintains a restrictive controlled-substance regime: pharmaceutical esketamine (Spravato) is an authorised medicine in the EU and available in Finland under prescription and supervised administration, while generic ketamine is an established medical anaesthetic (and occasionally used off-label in psychiatric emergency settings) but psychedelic classical compounds (psilocybin, MDMA, DMT, 5-MeO-DMT, ibogaine, ayahuasca/DMT plant preparations, mescaline, and 2C-X) are scheduled as narcotics with no routine medical reimbursement except in authorised clinical research. Reimbursement of any medicine in Finland is governed by decisions of the Pharmaceuticals Pricing.